NDAORALTABLETPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
6
Mechanism of Action
Type II RAF Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Started Feb 2026
6 enrolled
Low-grade Glioma
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Started Sep 2022
57 enrolled
Craniopharyngioma, ChildCraniopharyngiomaRecurrent Craniopharyngioma
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Started May 2022
44 enrolled
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Started Jul 2021
23 enrolled
MelanomaSolid TumorCRAF Gene Amplification+20 more
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Started Apr 2021
141 enrolled
Low-grade GliomaAdvanced Solid Tumor
Loss of Exclusivity
LOE Date
Jun 23, 2035
113 months away
Patent Expiry
Jun 23, 2035
Exclusivity Expiry
Apr 23, 2031